New Millennium Group’s Royalty Pharma RPRX Stock Holding History

New Millennium Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11	Closed	-$281	–	603
2024 Q4	$281	Buy	+11	New	+$292	﹤0.01%	559

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

New Millennium Group's RPRX Position: Q1 2025 in Review

New Millennium Group sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 11 shares — an estimated $281 sold.

New Millennium Group first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $281 in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

New Millennium Group reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
New Millennium Group sold 11 Royalty Pharma shares in Q1 2025, an estimated $281.
New Millennium Group first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
New Millennium Group's Royalty Pharma position peaked at $281 in Q4 2024.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on New Millennium Group's 13F filing for Q1 2025, filed 25 Apr 2025.